Evidence Hub

The influence of microvascular disease on cardiovascular events in type 2 diabetes: a post HOC analysis of empa-REG outcome

S. Verma, C. Wanner, I. Zwiener, A. Ofstad, J. George, D. Fitchett, B. Zinman

Journal of the American College of Cardiology, 2019

2 citations

Abstract

In people with type 2 diabetes (T2D) and macrovascular disease, the impact of coexistent microvascular disease on cardiovascular (CV) outcomes is unclear. We evaluated the relationship between baseline (BL) history of microvascular disease and CV outcomes in the EMPA-REG OUTCOME study.

Patients

How strong is the evidence?

Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free